Hanson Kristopher 4
4 · MapLight Therapeutics, Inc. · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) GC Kristopher Hanson Sells 13,917 Shares (~$419K)
What Happened
Kristopher Hanson, General Counsel of MapLight Therapeutics (MPLT), sold a total of 13,917 shares on May 11, 2026 in a series of open-market transactions. The four reported sales were: 284 shares at a weighted avg $27.61 ($7,841), 846 shares at $28.70 ($24,280), 6,979 shares at $30.04 ($209,649), and 5,808 shares at $30.56 ($177,492), for aggregate proceeds of approximately $419,262. These were sales (S) — routine dispositions rather than purchases.
Key Details
- Transaction date: May 11, 2026; filing date (Form 4 accession): May 11, 2026 (appears timely).
- Total shares sold: 13,917; total proceeds: ~$419,262.
- Reported prices are weighted averages and were sold in multiple executions; per-footnote price ranges: 27.26–28.08, 28.30–29.183, 29.305–30.2965, and 30.305–30.90 (see F2–F5).
- Footnote F1 indicates at least one of the transactions was executed pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on December 29, 2025.
- Shares owned after the transaction are not specified in the material provided here.
Context
These were open-market sales by a company insider. Sales executed under a pre-established 10b5‑1 plan are typically scheduled trades and do not, by themselves, indicate a change in an insider’s view of the company. This summary is factual only and does not speculate on motivations. If you want, I can pull the full Form 4 text or confirm post-transaction holdings from the filing.
Insider Transaction Report
- Sale
Voting Common Stock
[F1][F2]2026-05-11$27.61/sh−284$7,841→ 175,964 total - Sale
Voting Common Stock
[F1][F3]2026-05-11$28.70/sh−846$24,280→ 175,118 total - Sale
Voting Common Stock
[F1][F4]2026-05-11$30.04/sh−6,979$209,649→ 168,139 total - Sale
Voting Common Stock
[F1][F5]2026-05-11$30.56/sh−5,808$177,492→ 162,331 total
Footnotes (5)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.2965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.